Diabetic macular edema (DME) is the most common vision-threatening complication arising from diabetic retinopathy (DR).Globally, approximately 5.5% of individuals with diabetes are affected by DME (Im et al., 2022).Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents has become the first-line treatment for DME owing to their potent anti-permeability and anti-angiogenic effects (Ehlers et al., 2022). The gene discussed is VEGFA; the disease is diabetic macular edema.